{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:20:39Z","timestamp":1791328839323,"version":"4.3.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.mce.2003.10.008","type":"journal-article","created":{"date-parts":[[2003,12,4]],"date-time":"2003-12-04T12:02:13Z","timestamp":1070539333000},"page":"45-52","source":"Crossref","is-referenced-by-count":93,"title":["The 45-year story of the development of an anti-aldosterone more specific than spironolactone"],"prefix":"10.1016","volume":"217","author":[{"given":"Jo\u00ebl","family":"M\u00e9nard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2003.10.008_BIB1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(97)07306-6","article-title":"Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London","volume":"351","author":"Baker","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2003.10.008_BIB2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0002-8703(73)90051-3","article-title":"The use of spironolactone in the diagnosis and the treatment of hypertension associated with mineralocorticoid excess","volume":"86","author":"Beevers","year":"1973","journal-title":"Am. Heart J."},{"key":"10.1016\/j.mce.2003.10.008_BIB3","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0002-9149(02)02580-8","article-title":"Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade","volume":"90","author":"Blaustein","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.48.3.491","article-title":"Spironolactone as a nonspecific treatment for primary aldosteronism","volume":"48","author":"Bravo","year":"1973","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2003.10.008_BIB5","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archinte.130.6.849","article-title":"The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone","volume":"130","author":"Carey","year":"1972","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB7","first-page":"3","article-title":"Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jama.1965.03090030022005","article-title":"Normokalemic primary aldosteronism: a detectable cause of curable \u201cessential\u201d hypertension","volume":"193","author":"Conn","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2003.10.008_BIB9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2003.10.008_BIB10","unstructured":"de Gasparo, M., Joss, U., Ramjoue, H.P., Whitebread, S.E., Haenni, H., Schenkel, L., Kraehenbuehl, C., Biollaz, M., Grob, J., Schmidlin, J., Wieland, P., Wehali, M.U., 1987. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650\u2013656."},{"key":"10.1016\/j.mce.2003.10.008_BIB11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","article-title":"Antialdosterones: incidence and prevention of sexual side effects","volume":"32","author":"de Gasparo","year":"1989","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.mce.2003.10.008_BIB12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/ajh\/6.8.641","article-title":"Aging and human hormonal and pressor responsiveness to angiotensin II infusion with simultaneous measurement of exogenous and endogenous angiotensin II","volume":"6","author":"Duggan","year":"1993","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.mce.2003.10.008_BIB13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00501468","article-title":"Suppression by the spironolactone metabolite canrenone of plasma testosterone in man","volume":"285","author":"Erbler","year":"1974","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.mce.2003.10.008_BIB14","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1093\/emboj\/17.12.3317","article-title":"Antagonism in the human mineralocorticoid receptor","volume":"17","author":"Fagart","year":"1998","journal-title":"EMBO J."},{"key":"10.1016\/j.mce.2003.10.008_BIB15","doi-asserted-by":"crossref","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","article-title":"Multiple aspects of mineralocorticoid selectivity","volume":"280","author":"Farman","year":"2001","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1046\/j.1440-1681.2001.03585.x","article-title":"Is primary aldosteronism underdiagnosed in clinical practice?","volume":"28","author":"Fiquet-Kempf","year":"2001","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB17","unstructured":"Froment, A., Milon, H., 1972. Etude en double aveugle de l\u2019adjonction de spironolactone au traitement antihypertenseur thiazidique. La fr\u00e9quence de la gyn\u00e9comastie au cours des traitements prolong\u00e9s. Extrarenal activity of aldosterone and its antagonists, E. Medica. Amsterdam, pp. 64\u201369."},{"key":"10.1016\/j.mce.2003.10.008_BIB18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.mce.2003.10.008_BIB19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(94)93003-1","article-title":"Mineralocorticoid hypertension","volume":"344","author":"Gordon","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2003.10.008_BIB20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.225.1.40","article-title":"Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program","volume":"225","author":"Greenblatt","year":"1973","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2003.10.008_BIB21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jama.223.1.82b","article-title":"Gynecomastia and impotence: complications of spironolactone therapy","volume":"223","author":"Greenblatt","year":"1973","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2003.10.008_BIB22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/hlca.19970800220","article-title":"Steroidal aldosterone antagonists: increased selectivity of 9a1 11-epoxy derivatives","volume":"80","author":"Grob","year":"1997","journal-title":"Helvetica Chem. Acta"},{"key":"10.1016\/j.mce.2003.10.008_BIB23","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2003.10.008_BIB24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/bmj.323.7311.497","article-title":"Beneficial effects of potassium","volume":"323","author":"He","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.mce.2003.10.008_BIB25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cpt1978244465","article-title":"Gynecomastia induced in normal males by spironolactone","volume":"24","author":"Huffman","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.mce.2003.10.008_BIB26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/0002-9149(88)90551-6","article-title":"Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension","volume":"62","author":"Jeunemaitre","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB27","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB28","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0140-6736(02)98858-6","article-title":"Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial","volume":"359","author":"John","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2003.10.008_BIB29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00004872-199001000-00003","article-title":"Commentary. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations by Hans R. Brunner, J. M\u00e9nard et al","volume":"8","author":"Kaplan","year":"1990","journal-title":"J. Hypertens."},{"key":"10.1016\/j.mce.2003.10.008_BIB30","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1210\/jcem-15-10-1194","article-title":"The metabolic effects of progesterone in man","volume":"15","author":"Landau","year":"1955","journal-title":"J. Clin. Endocrinol."},{"key":"10.1016\/j.mce.2003.10.008_BIB31","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.HYP.37.2.806","article-title":"K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion","volume":"37","author":"Laragh","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.mce.2003.10.008_BIB32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.272.5262.676","article-title":"Molecular genetics of human blood pressure variation","volume":"272","author":"Lifton","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.mce.2003.10.008_BIB33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","article-title":"Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor","volume":"71","author":"Lombes","year":"1992","journal-title":"Circ. Res."},{"key":"10.1016\/j.mce.2003.10.008_BIB34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/0003-4819-85-5-630","article-title":"Spironolactone and endocrine dysfunction","volume":"85","author":"Loriaux","year":"1976","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB35","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.1963.73700230005018","article-title":"Gynecomastia during therapy with spironolactone","volume":"184","author":"Mann","year":"1963","journal-title":"JAMA"},{"issue":"Suppl. 1","key":"10.1016\/j.mce.2003.10.008_BIB36","first-page":"219s","article-title":"Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension","volume":"45","author":"Mantero","year":"1973","journal-title":"Clin. Sci. Mol. Med. Suppl."},{"key":"10.1016\/j.mce.2003.10.008_BIB37","first-page":"49","article-title":"Evaluation of aldosterone antagonists in healthy man","volume":"4","author":"McInnes","year":"1982","journal-title":"Methods Find Exp. Clin. Pharmacol."},{"key":"10.1016\/j.mce.2003.10.008_BIB38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1471-4892(01)00022-4","article-title":"Recent studies with eplerenone, a novel selective aldosterone receptor antagonist","volume":"1","author":"McMahon","year":"2001","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.mce.2003.10.008_BIB39","unstructured":"M\u00e9nard, J., Weil, B., Safar, M., Fendler, J., Legrand, J., Meyer, P., Vaysse, J., Milliez, P., 1970. Bases physiopathologiques du diagnostic et du traitement de l\u2019hyperaldost\u00e9ronisme primaire. In: Paul Milliez (Ed.), Acquisitions m\u00e9dicales r\u00e9centes. L\u2019Expansion Scientifique, Paris, pp. 321\u2013342."},{"key":"10.1016\/j.mce.2003.10.008_BIB40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2265.1978.tb01510.x","article-title":"Increased serum oestrone and oestradiol following spironolactone administration in hypertensive men","volume":"9","author":"Miyatake","year":"1978","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.mce.2003.10.008_BIB41","first-page":"995","article-title":"R\u00e9sultats du traitement chirurgical des ad\u00e9nomes de Conn","volume":"6","author":"Pagny","year":"1987","journal-title":"Arch. Mal. Coeur."},{"key":"10.1016\/j.mce.2003.10.008_BIB42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1440-1681.1987.tb02422.x","article-title":"High affinity aldosterone binding situ (type 1 receptors) in rat heart","volume":"14","author":"Pearce","year":"1987","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB43","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB44","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB45","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1210\/en.2002-220708","article-title":"The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related","volume":"144","author":"Rafestin-Oblin","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2003.10.008_BIB46","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/jcem-18-7-787","article-title":"Effect of an aldosterone antagonist on sodium and potassium excretion in primary hyperaldosteronism","volume":"18","author":"Salassa","year":"1958","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2003.10.008_BIB48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-69-4-685","article-title":"Aldosteronism in hypertension. The spironolactone response test","volume":"69","author":"Spark","year":"1968","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archinte.133.2.205","article-title":"Low-renin hypertension. Restoration of normotension and renin responsiveness","volume":"133","author":"Spark","year":"1974","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB50","doi-asserted-by":"crossref","first-page":"F559","DOI":"10.1152\/ajprenal.00320.2001","article-title":"New ideas about aldosterone signaling in epithelia","volume":"282","author":"Stockand","year":"2002","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB51","doi-asserted-by":"crossref","unstructured":"The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting-enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288, 2981\u20132997.","DOI":"10.1001\/jama.288.23.2981"},{"key":"10.1016\/j.mce.2003.10.008_BIB52","doi-asserted-by":"crossref","unstructured":"The HOPE investigators 2000. Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients, N. Engl. J. Med. 342, 145\u2013153.","DOI":"10.1056\/NEJM200001203420301"},{"key":"10.1016\/j.mce.2003.10.008_BIB53","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/BF00544063","article-title":"Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism","volume":"28","author":"Ulmann","year":"1985","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.mce.2003.10.008_BIB54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9149(73)80044-X","article-title":"Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone","volume":"32","author":"Vaughan","year":"1973","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB55","doi-asserted-by":"crossref","first-page":"558","DOI":"10.7326\/0003-4819-87-5-558","article-title":"Disparate patterns of aldosterone response during diuretic treatment of hypertension","volume":"87","author":"Weber","year":"1977","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB56","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3109\/10641968209061637","article-title":"Recurrence of hypertension in primary aldosteronism after discontinuation of spironolactone. Time course of changes in cardiac output and body fluid volumes","volume":"4","author":"Wenting","year":"1982","journal-title":"Clin. Exp. Hypertens A"},{"key":"10.1016\/j.mce.2003.10.008_BIB57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0889-8529(18)30106-3","article-title":"Essential hypertension as an endocrine disease","volume":"23","author":"Williams","year":"1994","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.mce.2003.10.008_BIB58","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.204.9.775","article-title":"Antihypertensive actions of diuretics. Comparative study of an aldosterone antagonist and a thiazide, alone and together","volume":"204","author":"Winer","year":"1968","journal-title":"JAMA"},{"key":"10.1016\/j.mce.2003.10.008_BIB59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archinte.123.4.366","article-title":"Effect of an adrenal inhibitor in hypertensive patients with suppressed renin","volume":"123","author":"Woods","year":"1969","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.mce.2003.10.008_BIB60","first-page":"R825","article-title":"Potassium\u2019s cardiovascular protective mechanisms","volume":"268","author":"Young","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.mce.2003.10.008_BIB61","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00004872-200208000-00002","article-title":"Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system","volume":"20","author":"Young","year":"2002","journal-title":"J. Hypertens."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720703003794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720703003794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T16:28:48Z","timestamp":1585326528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720703003794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":61,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0303720703003794"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2003.10.008","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}